Athersys to Host Shareholder Conference Call

CLEVELAND, April 24, 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will be hosting a shareholder conference call on Wednesday, April 29, 2015 to present the recently announced interim results of its exploratory Phase 2 clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who have suffered an ischemic stroke.

The conference call will begin at 2:00 PM EDT and will be hosted by Dr. Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys. Joining Dr. Van Bokkelen on the call will be Dr. David Hess, stroke specialist and Chairman of the Department of Neurology at the Medical College of Georgia at Georgia Regents University, and Dr. Lawrence Wechsler, Professor of Neurology and Chair of the Department of Neurology at the University of Pittsburgh. Both Drs. Hess and Wechsler are clinical investigators for the study and are recognized as independent experts and key opinion leaders in the field of stroke treatment.

Athersys will host the call as follows:

Date April 29, 2015
Time 2:00 p.m. (Eastern Time)
Telephone access: US and Canada 800-273-1254
Telephone access: International 973-638-3440
Access code 35326665
Live webcast under Investors section

A replay will be available for on-demand listening shortly after the completion of the call until 11:59 PM EDT on May 13, 2015 at the aforementioned URL, or by dialing 800-585-8367 or 855-859-2056 in the U.S. and Canada, or from abroad 404-537-3406, and entering access code 35326665.

About Athersys

Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at

CONTACT: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900

Source:Athersys, Inc.